Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of DS-5670a COVID-19 vaccine in healthy Japanese adults and elderly subjects
jRCT2071200110Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of DS-5670a in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety and Immunogenicity. Started Mar 2021; status: completed.
02
Drugs
DS-5670a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071200110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200110.